ScoreWhy is Zentalis Pharmaceuticals, Inc. ?
1
The company declared negative results in Mar'25 after positive results in Dec'24
- NET SALES(9M) At USD 26.86 MM has Grown at -33.76%
- DEBT-EQUITY RATIO (HY) Highest at -95.49 %
2
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -58.86%, its profits have fallen by -21.9%
3
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -58.86% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Zentalis Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Zentalis Pharmaceuticals, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Zentalis Pharmaceuticals, Inc.
-58.33%
-0.98
87.99%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
94.55%
EBIT Growth (5y)
-182.82%
EBIT to Interest (avg)
-188.53
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.13
Sales to Capital Employed (avg)
0.12
Tax Ratio
0.16%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.37
EV to EBIT
1.12
EV to EBITDA
1.13
EV to Capital Employed
6.02
EV to Sales
-8.30
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
537.80%
ROE (Latest)
-71.60%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend15What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -151.09 MM
OPERATING PROFIT(Q)
Highest at USD -35.9 MM
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 21.9 times
PRE-TAX PROFIT(Q)
Highest at USD -26.87 MM
NET PROFIT(Q)
Highest at USD -26.87 MM
EPS(Q)
Highest at USD -0.37
-5What is not working for the Company
NET SALES(9M)
At USD 26.86 MM has Grown at -33.76%
DEBT-EQUITY RATIO
(HY)
Highest at -95.49 %
Here's what is working for Zentalis Pharmaceuticals, Inc.
Operating Cash Flow
Highest at USD -151.09 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Operating Profit
Highest at USD -35.9 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD -26.87 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Pre-Tax Profit
At USD -26.87 MM has Grown at 69.47%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -26.87 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Net Profit
At USD -26.87 MM has Grown at 69.56%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD -0.37
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Debtors Turnover Ratio
Highest at 21.9 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Zentalis Pharmaceuticals, Inc.
Net Sales
At USD 26.86 MM has Grown at -33.76%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (USD MM)
Debt-Equity Ratio
Highest at -95.49 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
